The global in vitro diagnostics (IVD) market is entering a period of steady expansion as healthcare systems increasingly prioritize accurate, rapid, and personalized testing. The market was valued at USD 107.4 billion in 2025 and is expected to reach USD 111.0 billion in 2026. By 2033, the market is projected to grow to USD 160.7 billion, representing a 5.4% CAGR from 2026 to 2033.

North America led the global market in 2025, accounting for 47.3% of revenue, supported by advanced healthcare infrastructure, high diagnostic adoption, and strong investment in medical technologies. Meanwhile, Asia Pacific is expected to register the fastest CAGR through 2033, reflecting expanding healthcare access, rising disease burden, and increasing investment in diagnostic infrastructure.

What Is Driving Demand for IVD?

The growing prevalence of chronic diseases, infectious diseases, and genetic disorders is increasing the need for reliable diagnostic testing. Conditions including cancer, diabetes, Alzheimer’s disease, Parkinson’s disease, and Turner syndrome require increasingly sophisticated diagnostic approaches for screening, monitoring, and treatment decisions.

The healthcare sector is also moving toward early detection, preventive care, personalized medicine, and value-based healthcare. These shifts are increasing demand for diagnostic technologies capable of delivering faster results and clinically actionable information.

At the same time, advances in molecular diagnostics, next-generation sequencing (NGS), artificial intelligence (AI), machine learning, and data analytics are improving the accuracy and interpretation of diagnostic results. Digital integration enables diagnostic platforms to support more efficient clinical decision-making and, in some applications, predictive analysis.

The expansion of point-of-care testing (POCT) is another important growth opportunity. Rapid testing closer to the patient can shorten turnaround times and improve access to diagnostics, particularly in decentralized and emerging healthcare settings. Pandemic preparedness has further highlighted the strategic importance of scalable and rapid diagnostic capabilities.

Download a free sample report or claim your copy of this full market intelligence report

Key Market Trends and Segment Leaders

Several segments accounted for significant portions of the IVD market in 2025:

• By product: Reagents led with a 65.7% market share.
• By technology: Molecular diagnostics-based products accounted for 25.8%.
• By application: Infectious diseases represented the largest application segment at 39.7%.
• By end use: Hospitals held the leading position with a 44.5% share.

These segment dynamics reflect the central role of laboratory reagents, molecular testing, infectious disease diagnostics, and hospital-based testing within modern healthcare delivery.

Regional Outlook and Market Structure

North America's 47.3% revenue share in 2025 underscores its established position in the global IVD landscape. Mature healthcare systems, technological capabilities, diagnostic laboratories, and sustained innovation support the region's leadership.

Asia Pacific, however, offers substantial growth potential. Increasing healthcare expenditure, expanding diagnostic infrastructure, greater awareness of early disease detection, and the rising burden of chronic conditions are contributing to its expected position as the fastest-growing regional market during 2026–2033.

The market is characterized by continuous technological innovation and active consolidation. Companies are investing heavily in R&D to improve test sensitivity, specificity, speed, usability, and integration with digital healthcare systems. Molecular diagnostics, NGS, AI-enabled interpretation, and non-invasive testing remain important areas of innovation.

Mergers and acquisitions are also prominent as established companies seek to acquire innovative technologies, broaden their product portfolios, enter emerging diagnostic categories, and strengthen geographic reach. Smaller technology-focused companies can provide established players with access to specialized molecular, digital health, and data-driven diagnostic capabilities.

Looking for more in-depth data focusing on specific segments or regions? Get this report customized with inclusion of custom data sets to suit your exact business needs.

Market Size at a Glance

Chronic Disease Burden Strengthens the Diagnostic Case

The expanding global burden of chronic disease is reinforcing the importance of diagnostic testing. According to the U.S. Centers for Disease Control and Prevention (CDC), chronic diseases such as cancer, diabetes, chronic kidney disease, and chronic respiratory diseases account for approximately 7 in 10 deaths in the U.S. each year, while around 6 in 10 U.S. adults live with a chronic disease.

Beyond chronic conditions, infectious disease surveillance and preparedness remain critical. Rising diagnostic requirements across different geographic markets are encouraging healthcare providers and governments to strengthen laboratory capacity, rapid testing infrastructure, and disease-monitoring systems.

Leading Companies

The competitive landscape includes major global healthcare and diagnostics companies with broad capabilities across laboratory testing, molecular diagnostics, immunoassays, reagents, instruments, and digital solutions. Key companies profiled in the IVD market include:

• Abbott
• Thermo Fisher Scientific, Inc.
• Bio-Rad Laboratories, Inc.
• Siemens Healthineers AG
• bioMérieux
• BD
• QIAGEN
• QuidelOrtho

Explore the full list of profiled companies operating in this market with recent strategic initiatives

Explore our dedicated business services:

• S. Healthcare Facility Mapping & Intelligence Portal – Claims analytics (MS-DRG, service lines, ICD-10 outpatient, APC reimbursement, CPT-level) plus hospital-level financials (balance sheet, income statement, uncompensated care, financial health dashboards), covering 25,000+ healthcare facilities — including 7,000+ hospitals, independent pharmacies, freestanding EDs, concierge physicians, and ASCs.
• Brainshare Consulting – End-to-end business consulting services including Opportunity assessment, GTM support, Competitive intelligence, and Consumer Analytics.
• Custom Research – Get a market intelligence report tailored to your specific requirements and aligned with your business goals.
• Consumer Insights – Capture real, evolving consumer sentiment and behavior to help you make data driven strategies.
• Horizon Databooks – Access the world’s largest portal of Market Reports & Statistics
• Investment Insights – Make investment decisions with data driven insights, powered by domain and technology
• Signal (Pricing Intelligence) - Commodity price intelligence to drives strategic advantage.

About us:
Grand View Research, a market research and consulting company, provides syndicated research reports, customized research reports, and consulting services. Grand View Research database is used by the world's renowned academic institutions and Fortune 500 companies to understand the global and regional business environment. Our database features thousands of statistics and in-depth analysis on 46 industries in 25 major countries worldwide.